Become one of our almost 500 registered trial sites and register today! 

All you need to do is send an email to including:

  • Name of your site
  • Postal address
  • Full name of a contact person
  • Contact email address

VACCELERATE and its partners strongly condemn Russia’s attack on Ukraine in violation of international law. The Russian invasion of Ukraine is an indescribable assault on the pillars of our society: freedom, democracy, self-determination and integrity. Our full solidarity goes out to the Ukrainian people.

To express this solidarity, we have decided to deactivate the sites from Belarus and Russia that are represented in the EUVAP database. We do not know individual political views and we apologize for the inconvenience. Unfortunately, in this situation we cannot make individual decisions but have to take a clear position. The protection of our values is paramount for us.

We hope that the political situation will change as soon as possible, so that we will be able to reverse this decision.

What is EUVAP?

EUVAP is a platform for experienced clinical trial sites interested in conducting COVID-19 vaccine studies.

Clinical trial sites register with the EUVAP database by answering a short site questionnaire. Any clinical trial site from the European Union and neighbouring countries can register with EUVAP.

The EUVAP platform database is managed by the Clinical Trial Infrastructure of the German Center for Infection Research (DZIF) at the University of Cologne.

What does EUVAP seek to accomplish?

EUVAP aims to accelerate clinical development of COVID-19 vaccines for all populations and risk groups.
The EUVAP database allows for a Europe-wide mapping of experienced clinical trial sites interested in conducting COVID-19 vaccine trials.
EUVAP uses its database to put individual sites in contact with clinical trial sponsors, matching the characteristics of each site with the specific requirements of an individual trial.
EUVAP acts as an information broker or matchmaker between interested sites and sponsors, it is not a governing or management body for trial conduct. EUVAP interacts with established research networks but also with clinical trial sites not affiliated with a network.

EUVAP thereby intends to boost the conduct of clinical trials of any scale across country borders in specific populations and risk groups that are not the focus of ongoing phase III trials. There is no upfront limitation on study design: Studies may be head-to-head interventional or observational, on short-term or long-term outcomes, focusing on very small populations or else. Any sponsor from academia, small or medium enterprises (SME), biotech or pharmaceutical industry is welcome to contact EUVAP. In the long term, EUVAP is designed to roll out vaccine trials in indications beyond COVID-19.

What information will EUVAP ask for when you register your clinical trial site?

  • Name and type of institution, contact details
  • Affiliation with infectious disease networks
  • Prior clinical trial experience
  • Main area of expertise, e.g. disease or indication of interest
  • Infrastructure available at your site
  • Your preferences for COVID-19 vaccine studies, e.g. specific study populations, inpatient vs. outpatient setting etc.
  • You can also share the contacts of other sites you wish to recommend for EUVAP


477 clinical trial sites have joined EUVAP so far. The majority is either located in the EU or associated with the H2020 programme.

33 further study sites have expressed interest.

EUVAP laboratories

VACCELERATE Clinical Studies

Clinical trials serve the purpose of clarifying open questions regarding new vaccines, therapies or medicines. By participating in clinical trials, you can make a major contribution to scientific progress. As a study participant you support the research of diseases and the development of new treatment options and at the same time receive comprehensive medical care.

VACCELERATE is carrying out three COVID-19 vaccine trials. The results will be linked here as soon as they are published. 


A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS-CoV-2

Lead: Oliver Cornely, Institution/Sponsor: UHC, Germany



An International Multicentre, Phase 2, Randomised, Adaptive Protocol to Determine the Need for, Optimal Timing of and Immunogenicity of Administering a 4th Homologous mRNA Vaccination Dose against SARS-CoV-2 in the General Population (18+ years) Already Vaccinated with the BNT162b2 Vaccine

Lead: Patrick Mallon, Institution/Sponsor: NUID UCD, Ireland



A Phase 2, Comparative Randomised Trial to Evaluate the Impact of Reduced COVID‐19 mRNA Vaccination Regimen on Immunological Responses and Reactogenicity in Paediatric Subjects with Prior SARS‐CoV‐2 Immunity

Lead: Patricia Bruijning-Verhagen, Institution/Sponsor: UMCU, Netherlands

CECAD Newsletter 01/2022

CECAD Excellent in Aging Research
Cluster of Excellence at the University of Cologne

Learn more about the involvement of LAB-Net, the Central Laboratory at the University of Antwerp, in AGED and BOOSTAVAC:


GCP Course

The COMBACTE online GCP training offers practical guidance to optimize the often-so-difficult recruitment of patients and to support the performance of investigators in clinical trials. The course is provided through the European Centre for Clinical Research Training (ECCRT) and is available on the ECCRT virtual campus. The training enables participants to understand the responsibilities of everyone involved in clinical research. It teaches the conduct, performance, monitoring and reporting of a clinical trial using interactive quizzes and exercises for self-assessment. A trainer from ECCRT is available to discuss questions.

The course takes approximately seven hours. It can be started and stopped at any time, and can be completed within three months after registration. Participants’ knowledge on GCP will be tested with a final exam. Upon successfully completing the course, an official GCP certificate can be downloaded.

The GCP training meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by “TransCelerate BioPharma” as necessary to enable mutual recognition of GCP training among trial sponsors. The training is complete and up to date, including the ICH-GCP E6 (R2) Addendum 2016.



Following soon:

  • Study Nurse Course
  • Clinical Development of a Vaccine Course
  • Management of Multinational Trials Course

The COVID-NMA initiative – A living mapping and living systematic review of Covid-19 trials

Launched in March 2020, COVID-NMA is an international initiative working in conjunction with the World Health Organization (WHO), led by a team of researchers from Cochrane and other institutions (Université de Paris, Inserm, CNRS, Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Odense University Hospital, Epistemonkos Foundation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan).

The mission is to inform research planning by producing an up-to-date mapping of trial evidence, to inform public health and healthcare decisions by producing relevant, accessible, up-to-date, and trustworthy synthesis of high-quality evidence  about the efficacy and safety of interventions for the prevention or treatment of COVID-19 and to improve research value by producing a living monitoring of trial planning, conduct, and reporting  and implementing interventions to transform research practices.

For more information: